Clinical Trials Collective Data Document 
Cannabis Law Report
DECEMBER 2, 2021
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
Veriheal
JUNE 30, 2023
For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 28, 2021
Reporting to the Regulatory Affairs Manager, the RPS supports functions related to tracking regulatory information and document styling and publishing in eCTD format for regulatory submissions. Position duties: Electronic document preparation and submission of electronic common technical document (eCTD) submissions to regulatory agencies.
Cannabis Law Report
FEBRUARY 5, 2022
Responsible for creation and maintenance of all regulatory documentation, including but not limited to, product packaging, labelling, inserts, working in conjunction with the marketing team for design, and assuring regulatory compliance across all territories. Support new product development and further clinical activities.
Cannabis Law Report
DECEMBER 15, 2021
Responsible for creation and maintenance of all regulatory documentation, including but not limited to, product packaging, labelling, inserts, working in conjunction with the marketing team for design, and assuring regulatory compliance across all territories. Support new product development and further clinical activities. 2 days ago.
Cannabis Law Report
FEBRUARY 2, 2022
– Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA). Dr. Manalo-Morgan has spent the last 5 years researching cannabis and has specialized in the formulation of cannabinoid products for clinical trials.
Cannabis Law Report
JANUARY 6, 2022
Following his successful tenure at Amazon, Leslie made the leap to the burgeoning cannabis industry where he served as CEO of one of the world’s most authoritative digital cannabis data sources, Leafly. This document contains forward-looking statements. The synergies could not be better aligned,” Leslie said. “I
Expert insights. Personalized for you.
52 
Let's personalize your content